20/20 Biolabs, Inc. (AIDX)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Jonathan Cohen
|
Founder, CEO, President & Director | 325.5k | -- | 1964 |
|
Dr. Jiming Zhou Ph.D.
|
Chief Operating Officer | 225.65k | -- | 1968 |
|
Dr. Michael Saul Lebowitz Ph.D.
|
Chief Scientific Officer | 89.6k | -- | 1969 |
|
Mr. Alan B. Bergman
|
Chief Financial Officer | -- | -- | 1969 |
|
Mr. David Lees
|
Director of Sales | -- | -- | -- |
|
Mr. Ronald R. Baker
|
Chief Business Officer | -- | -- | 1951 |
|
Marc Gordon
|
Controller | -- | -- | -- |
20/20 Biolabs, Inc.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 4
Description
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
